ALS play­er Amy­lyx bags $190M as it sets sail on Nas­daq amid chop­py wa­ters

ALS drug de­vel­op­er Amy­lyx got off its IPO on Fri­day, rais­ing $190 mil­lion af­ter pric­ing its stock at the midrange of the of­fer­ing and bump­ing up the of­fer­ing by 1.2 mil­lion shares.

Com­ing out at $19 a share, the biotech $AM­LX is in a small group of drug de­vel­op­ers that is test­ing some very chop­py wa­ters on Nas­daq at the be­gin­ning of 2022. Last year’s of­fer­ings are gen­er­al­ly un­der­wa­ter on of­fer­ing price as in­vestors grew in­creas­ing­ly dis­en­chant­ed with a sec­tor that has grown sig­nif­i­cant­ly in re­cent years — with a stint in the red-hot zone in 2020.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER